MX360062B - Metodos de elaboracion de fenilacetato de l-ornitina. - Google Patents
Metodos de elaboracion de fenilacetato de l-ornitina.Info
- Publication number
- MX360062B MX360062B MX2013003764A MX2013003764A MX360062B MX 360062 B MX360062 B MX 360062B MX 2013003764 A MX2013003764 A MX 2013003764A MX 2013003764 A MX2013003764 A MX 2013003764A MX 360062 B MX360062 B MX 360062B
- Authority
- MX
- Mexico
- Prior art keywords
- phenylacetate
- ornitine
- elaboration
- methods
- processes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/32—Phenylacetic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39058510P | 2010-10-06 | 2010-10-06 | |
| PCT/US2011/054983 WO2012048043A1 (en) | 2010-10-06 | 2011-10-05 | Methods of making l-ornithine phenyl acetate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013003764A MX2013003764A (es) | 2013-05-20 |
| MX360062B true MX360062B (es) | 2018-10-22 |
Family
ID=45928120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013003764A MX360062B (es) | 2010-10-06 | 2011-10-05 | Metodos de elaboracion de fenilacetato de l-ornitina. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8946473B2 (enExample) |
| EP (1) | EP2625162B1 (enExample) |
| JP (1) | JP6087284B2 (enExample) |
| KR (1) | KR101888215B1 (enExample) |
| CN (1) | CN103502203B (enExample) |
| AU (1) | AU2011312042B2 (enExample) |
| BR (1) | BR112013008054B1 (enExample) |
| CA (1) | CA2813563C (enExample) |
| EA (1) | EA028395B1 (enExample) |
| ES (1) | ES2720148T3 (enExample) |
| IL (1) | IL225512A (enExample) |
| MX (1) | MX360062B (enExample) |
| NZ (1) | NZ609191A (enExample) |
| SG (1) | SG189231A1 (enExample) |
| TR (1) | TR201903978T4 (enExample) |
| WO (1) | WO2012048043A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1824563T3 (pl) | 2004-11-26 | 2010-07-30 | Ucl Business Plc | Kompozycje zawierające ornitynę i fenylooctan lub fenylomaślan do leczenia encefalopatii wątrobowej |
| SG174982A1 (en) | 2009-04-03 | 2011-11-28 | Ocera Therapeutics Inc | L-ornithine phenyl acetate and methods of making thereof |
| JP5749255B2 (ja) | 2009-06-08 | 2015-07-15 | ユーシーエル ビジネス ピーエルシー | Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 |
| JP6087284B2 (ja) | 2010-10-06 | 2017-03-01 | オセラ セラピューティクス， インコーポレイテッド | Ｌ−オルニチンフェニルアセテートを製造するための方法 |
| IL281349B (en) | 2014-11-24 | 2022-09-01 | Ucl Business Ltd | Treatment of diseases related to hepatic stellate cell activity using ammonia-lowering treatments |
| CA2983146C (en) | 2015-04-20 | 2023-09-12 | Ocera Therapeutics, Inc. | Formulations of l-ornithine phenylacetate |
| US10835506B2 (en) | 2015-08-18 | 2020-11-17 | Ocera Therapeutics, Inc. | Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
| US11219611B2 (en) | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
| SG11201802987UA (en) * | 2015-11-13 | 2018-05-30 | Ocera Therapeutics Inc | Formulation of l-ornithine phenylacetate |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| CA3063134A1 (en) * | 2017-05-11 | 2018-11-15 | Ocera Therapeutics, Inc. | Processes of making l-ornithine phenylacetate |
| US10682325B2 (en) | 2017-08-14 | 2020-06-16 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting |
| JP2021527670A (ja) | 2018-06-20 | 2021-10-14 | アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． | 筋肉中の脂肪浸潤の治療のための組成物及び方法 |
| JP2022533569A (ja) | 2019-05-09 | 2022-07-25 | オセラ セラピューティクス， インコーポレイテッド | 肝性脳症を評価および処置する方法 |
| WO2024261477A1 (en) | 2023-06-20 | 2024-12-26 | Yaqrit Limited | Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB965637A (en) | 1962-04-23 | 1964-08-06 | Tanabe Seiyaku Co | L-ornithine l-aspartate |
| NL302572A (enExample) | 1962-12-27 | |||
| GB1067742A (en) | 1963-09-16 | 1967-05-03 | Kyowa Hakko Kogyo Kk | Process for the preparation of l-ornithine l-aspartate |
| ZA716628B (en) | 1970-10-15 | 1972-06-28 | Richardson Merrell Spa | Composition and method for treatment of hepatic disease and mental fatigue |
| US4100161A (en) | 1974-04-15 | 1978-07-11 | The Johns Hopkins University | Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids |
| US3950529A (en) | 1975-02-03 | 1976-04-13 | Massachusetts General Hospital | Amino acid formulations for patients with liver disease and method of using same |
| US4228099A (en) | 1978-03-17 | 1980-10-14 | The Johns Hopkins University | Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders |
| US4320146A (en) | 1978-03-17 | 1982-03-16 | The Johns Hopkins University | Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids |
| US4352814A (en) | 1979-04-18 | 1982-10-05 | The Johns Hopkins University | Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs |
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
| US5591613A (en) | 1990-07-02 | 1997-01-07 | Degussa Aktiengesellschaft | Method for the preparation of D-arginine and L-ornithine |
| DE4020980C1 (enExample) | 1990-07-02 | 1991-09-26 | Degussa Ag, 6000 Frankfurt, De | |
| JP3127484B2 (ja) | 1991-02-28 | 2001-01-22 | 味の素株式会社 | 肝炎治療薬 |
| US5767086A (en) | 1992-04-03 | 1998-06-16 | Terrapin Technologies, Inc. | Bone marrow stimulation by certain glutathione analogs |
| ATE153299T1 (de) | 1992-09-09 | 1997-06-15 | Fisons Plc | Pharmazeutisches verpacken |
| US5571783A (en) | 1993-03-09 | 1996-11-05 | Clintec Nutrition Company | Composition and method for treating patients with hepatic disease |
| JP3273578B2 (ja) * | 1993-09-21 | 2002-04-08 | 第一化学薬品株式会社 | オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法 |
| US5840891A (en) | 1994-07-28 | 1998-11-24 | Syntex (U.S.A.) Inc. | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative |
| WO1997030167A1 (en) | 1996-02-13 | 1997-08-21 | The Trustees Of The University Of Pennsylvania | Method of treating liver disorders |
| ZA986614B (en) | 1997-07-25 | 1999-01-27 | Gilead Sciences | Nucleotide analog composition |
| GB9815567D0 (en) | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| US6258849B1 (en) | 1998-07-23 | 2001-07-10 | Stanislaw R. Burzynski | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
| CA2374273A1 (en) | 1999-05-21 | 2000-11-30 | Takeda Chemical Industries, Ltd. | Liver function controlling agents |
| US6768024B1 (en) | 2000-08-04 | 2004-07-27 | Lion Bioscience Ag | Triamine derivative melanocortin receptor ligands and methods of using same |
| JP3211824B1 (ja) | 2000-10-26 | 2001-09-25 | 味の素株式会社 | 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法 |
| EP1374863B1 (en) | 2001-03-15 | 2009-09-02 | Riken | Amino acid compositions for ameliorating liver failure |
| US6503530B1 (en) | 2001-11-01 | 2003-01-07 | Chunghee Kimberly Kang | Method of preventing development of severe metabolic derangement in inborn errors of metabolism |
| US20030105104A1 (en) | 2001-11-27 | 2003-06-05 | Burzynski Stanislaw R. | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
| US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| CN1383815A (zh) | 2002-05-08 | 2002-12-11 | 刘万忠 | 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法 |
| US20040152784A1 (en) | 2002-07-23 | 2004-08-05 | Special Products Limited | Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia |
| EP1541141A1 (en) | 2002-08-30 | 2005-06-15 | Ajinomoto Co., Inc. | Therapeutic agent for hepatic disease |
| US20050059150A1 (en) | 2003-09-17 | 2005-03-17 | Becton, Dickinson And Company | Environments that maintain function of primary liver cells |
| MXPA03009902A (es) * | 2003-10-29 | 2005-05-03 | Manuel Francisco Lara Och Jose | Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio. |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| CN101010087B (zh) | 2004-05-06 | 2012-06-27 | 奥斯泰奥洛吉斯公司 | 用于制备金属有机盐的高收率和快速的合成方法 |
| US20060045912A1 (en) | 2004-08-30 | 2006-03-02 | Peter Truog | 4-phenylbutyric acid controlled-release formulations for therapeutic use |
| PL1824563T3 (pl) | 2004-11-26 | 2010-07-30 | Ucl Business Plc | Kompozycje zawierające ornitynę i fenylooctan lub fenylomaślan do leczenia encefalopatii wątrobowej |
| HRP20140476T1 (hr) | 2005-11-17 | 2014-07-18 | Silverstone Pharma Est. | Stabilni oblik amorfnih soli perindoprila, postupak njihove pripreme, posebno industrijske pripreme i njihova uporaba u lijeäśenju hipertenzije |
| CN201421432Y (zh) * | 2009-02-20 | 2010-03-10 | 山东师范大学 | 一种相干衍射成像处理装置 |
| SG174982A1 (en) | 2009-04-03 | 2011-11-28 | Ocera Therapeutics Inc | L-ornithine phenyl acetate and methods of making thereof |
| JP5749255B2 (ja) | 2009-06-08 | 2015-07-15 | ユーシーエル ビジネス ピーエルシー | Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 |
| JP6087284B2 (ja) | 2010-10-06 | 2017-03-01 | オセラ セラピューティクス， インコーポレイテッド | Ｌ−オルニチンフェニルアセテートを製造するための方法 |
-
2011
- 2011-10-05 JP JP2013532925A patent/JP6087284B2/ja not_active Expired - Fee Related
- 2011-10-05 EP EP11831546.4A patent/EP2625162B1/en active Active
- 2011-10-05 CN CN201180058441.1A patent/CN103502203B/zh not_active Expired - Fee Related
- 2011-10-05 TR TR2019/03978T patent/TR201903978T4/tr unknown
- 2011-10-05 KR KR1020137011664A patent/KR101888215B1/ko active Active
- 2011-10-05 EA EA201390403A patent/EA028395B1/ru not_active IP Right Cessation
- 2011-10-05 MX MX2013003764A patent/MX360062B/es active IP Right Grant
- 2011-10-05 CA CA2813563A patent/CA2813563C/en active Active
- 2011-10-05 WO PCT/US2011/054983 patent/WO2012048043A1/en not_active Ceased
- 2011-10-05 SG SG2013024559A patent/SG189231A1/en unknown
- 2011-10-05 ES ES11831546T patent/ES2720148T3/es active Active
- 2011-10-05 NZ NZ609191A patent/NZ609191A/en not_active IP Right Cessation
- 2011-10-05 US US13/878,146 patent/US8946473B2/en active Active
- 2011-10-05 AU AU2011312042A patent/AU2011312042B2/en not_active Ceased
- 2011-10-05 BR BR112013008054-0A patent/BR112013008054B1/pt not_active IP Right Cessation
-
2013
- 2013-04-02 IL IL225512A patent/IL225512A/en active IP Right Grant
-
2015
- 2015-01-21 US US14/601,591 patent/US9260379B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2813563C (en) | 2019-02-26 |
| EP2625162A4 (en) | 2014-06-25 |
| BR112013008054A2 (pt) | 2016-06-14 |
| EA028395B1 (ru) | 2017-11-30 |
| JP6087284B2 (ja) | 2017-03-01 |
| AU2011312042A1 (en) | 2013-05-02 |
| MX2013003764A (es) | 2013-05-20 |
| JP2013542935A (ja) | 2013-11-28 |
| NZ609191A (en) | 2015-06-26 |
| US20130211135A1 (en) | 2013-08-15 |
| EP2625162B1 (en) | 2019-03-13 |
| TR201903978T4 (tr) | 2019-04-22 |
| CN103502203A (zh) | 2014-01-08 |
| EP2625162A1 (en) | 2013-08-14 |
| IL225512A (en) | 2017-12-31 |
| SG189231A1 (en) | 2013-05-31 |
| WO2012048043A1 (en) | 2012-04-12 |
| KR20140053807A (ko) | 2014-05-08 |
| IL225512A0 (en) | 2013-06-27 |
| US20150133684A1 (en) | 2015-05-14 |
| BR112013008054B1 (pt) | 2019-04-09 |
| ES2720148T3 (es) | 2019-07-18 |
| US9260379B2 (en) | 2016-02-16 |
| CN103502203B (zh) | 2016-09-07 |
| CA2813563A1 (en) | 2012-04-12 |
| US8946473B2 (en) | 2015-02-03 |
| AU2011312042B2 (en) | 2015-08-20 |
| KR101888215B1 (ko) | 2018-09-20 |
| EA201390403A1 (ru) | 2013-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX360062B (es) | Metodos de elaboracion de fenilacetato de l-ornitina. | |
| WO2011119004A3 (en) | Method of producing d-psicose crystals | |
| EA201400483A1 (ru) | Составы собирателей и способы их применения | |
| EA201391389A1 (ru) | Кристаллы антител против склеростина и составы на их основе | |
| EA201391180A1 (ru) | Способ получения оптически активных производных дигидробензофурана | |
| EA202092987A2 (ru) | Липид, содержащий докозапентаеновую кислоту | |
| CL2012000590A1 (es) | Proceso para preparar w-transaminasa (r)-selectiva. | |
| EA201290988A1 (ru) | Стереоселективный синтез фосфорсодержащих активных соединений | |
| EA201391274A1 (ru) | Аминохинолины в качестве ингибиторов киназ | |
| ECSP11011348A (es) | 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3 | |
| BR112013027637A2 (pt) | processo para a preparação de um sal de metal trialcalino de l-mgda cristalino por cristalização, e, sal de metal trialcalino de l-mgda cristalino | |
| BR112013019520A2 (pt) | método para produção de 2,3-butanodiol por fermentação | |
| EA201391371A1 (ru) | Фармацевтическая композиция ситаглиптина | |
| ME03088B (me) | Postupak za proizvodnju stabilnog, injektabilnog rastvora noradrenalina niske koncentracije | |
| UY34108A (es) | ?proceso para la fabricación de sustratos revestidos?. | |
| CL2012002082A1 (es) | Proceso para la preparacion de lacosamida, por hidroximetilación; compuestos intermediarios. | |
| CL2012003491A1 (es) | Compuesto derivado de dihidropirrol sustituidos; proceso para preparar dichos derivados en forma estereoselectiva. | |
| CL2015002488A1 (es) | Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen | |
| BR112013016241A2 (pt) | composto, e, método para fabricar um composto | |
| PE20140386A1 (es) | Proceso para la produccion de fideos fritos | |
| EA201692288A1 (ru) | Способ получения фосфорсодержащих циангидринов | |
| BR112014010997A2 (pt) | processo para o preparo de ß-glicosídeos de c-arila | |
| CY1118514T1 (el) | Μεθοδος για την παρασκευη πεμετρεξιδης και αλατος λυσινης αυτης | |
| UA111333C2 (uk) | Спосіб одержання l-аргінінової солі периндроприлу | |
| ECSP11011346A (es) | 3-Amino-2-mercaptoquinolina sustituida como modulador de KCNQ2/3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |